Gavi terminates COVID vaccine deal with Clover, demands $224M repayment
International vaccine partnership Gavi has discontinued a COVID vaccine advance purchase agreement with Clover Biopharmaceuticals of China and is asking for repayment of $224 million.
International vaccine partnership Gavi has discontinued a COVID vaccine advance purchase agreement with Clover Biopharmaceuticals of China and is asking for repayment of $224 million.
